Blab Business
Eton Pharmaceuticals Accelerates Rare-Disease Portfolio with Increlex and Amglidia Acquisitions, Eyes 16-Product Line
Eton Pharmaceuticals (NASDAQ: ETON) announced that it has closed two acquisitions this quarter, adding the Increlex and Amglidia products to its portfolio of rare‑disease therapies. The deals bring the company’s commercial product count to 16 and are part of a strategy that targets two acquisitions per year. The move follows a 40 % year‑over‑year sales surge in the third quarter of 2024 and the company’s first reported profit.
In its Q3 2024 earnings release, Eton said it generated positive cash flow in the third quarter and expects continued positive cash flow in the fourth quarter. The company also announced an expansion of its existing credit facility to support the Increlex acquisition, which is valued at $22.5 million and is expected to close near year‑end 2024. The release noted that the acquisition is projected to be accretive to 2025 earnings.
The second acquisition, the U.S. rights to Amglidia (glyburide oral suspension), was announced in a separate press release. Amglidia has been approved by the European Medicines Agency and is commercially available in Europe. The U.S. Food and Drug Administration has granted it orphan drug designation, and the product is considered a strategic fit with Eton’s existing pediatric endocrinology focus.
Eton’s business model is built around acquiring ultra‑rare disease drugs and integrating them into a growing pipeline. According to the company’s website, it currently has 14 active programs, with several in lead or approval stages. Management has projected peak sales of $205 million for existing products and $185 million for pipeline products, with future acquisitions modeled at approximately $69.5 million by 2035.
Valuation analysts have updated their fair‑value estimates for ETON. A recent research note rated the stock as Hold, with a base‑case fair value of $38.75—about 7 % below the current trading level—and an optimistic estimate of $53. MarketBeat lists a current price target of $45.75, while Simply Wall St reports a market capitalization of roughly $889.7 million.
The company’s stock has risen sharply since the beginning of the year, but the author of the research note has trimmed the position and rolled up partially covered put options, resulting in a combined half‑position. The latest earnings report and acquisition announcements suggest that Eton is positioning itself for continued growth in the rare‑disease sector.
At this time, investors will be watching the upcoming earnings release for the fourth quarter, the finalization of the Increlex and Amglidia deals, and any updates on the company’s credit facility. The company’s strategy to add two acquisitions per year and expand its product line to 16 may influence future valuation models and investor sentiment.
In its Q3 2024 earnings release, Eton said it generated positive cash flow in the third quarter and expects continued positive cash flow in the fourth quarter. The company also announced an expansion of its existing credit facility to support the Increlex acquisition, which is valued at $22.5 million and is expected to close near year‑end 2024. The release noted that the acquisition is projected to be accretive to 2025 earnings.
The second acquisition, the U.S. rights to Amglidia (glyburide oral suspension), was announced in a separate press release. Amglidia has been approved by the European Medicines Agency and is commercially available in Europe. The U.S. Food and Drug Administration has granted it orphan drug designation, and the product is considered a strategic fit with Eton’s existing pediatric endocrinology focus.
Eton’s business model is built around acquiring ultra‑rare disease drugs and integrating them into a growing pipeline. According to the company’s website, it currently has 14 active programs, with several in lead or approval stages. Management has projected peak sales of $205 million for existing products and $185 million for pipeline products, with future acquisitions modeled at approximately $69.5 million by 2035.
Valuation analysts have updated their fair‑value estimates for ETON. A recent research note rated the stock as Hold, with a base‑case fair value of $38.75—about 7 % below the current trading level—and an optimistic estimate of $53. MarketBeat lists a current price target of $45.75, while Simply Wall St reports a market capitalization of roughly $889.7 million.
The company’s stock has risen sharply since the beginning of the year, but the author of the research note has trimmed the position and rolled up partially covered put options, resulting in a combined half‑position. The latest earnings report and acquisition announcements suggest that Eton is positioning itself for continued growth in the rare‑disease sector.
At this time, investors will be watching the upcoming earnings release for the fourth quarter, the finalization of the Increlex and Amglidia deals, and any updates on the company’s credit facility. The company’s strategy to add two acquisitions per year and expand its product line to 16 may influence future valuation models and investor sentiment.
